Background: This study was conducted to investigate whether mRNA vaccine technology could be adapted for the ectothermic vertebrate Atlantic salmon (Salmo salar). Lipid nanoparticle (LNP) technology has been developed and optimized for mRNA vaccines in mammals, stabilizing mRNA and facilitating its delivery into cells. However, its utility at the temperatures and specific biological environments present in ectotherms remains unclear. In addition, it is unknown if modified mRNA containing non-canonical nucleotides can correctly translate in salmonid cells. Methods: We used an mRNA transcript coding for enhanced green fluorescence protein, flanked by the untranslated regions of the hemagglutinin-esterase gene of the infectious salmon anemia virus, and a 120-base-long poly(A) tail. The mRNA was generated via in vitro transcription where uridine residues were replaced with N1-methyl-pseudouridines, and then encapsulated in LNPs. Results: When transfected into the salmonid cell line CHH-1, the mRNA-LNP construct induced expression of EGFP. Furthermore, when mRNA-LNPs were injected intramuscularly into salmon, in vivo protein expression was demonstrated via immunohistochemistry. EGFP was observed in cells infiltrating the spaces between muscle cells in a focal inflammatory response. Conclusion: The results indicate that N1-methyl-pseudouridine-modified mRNA encapsulated in LNPs can be used to express antigens of interest in salmonid fish.
Background: The study was conducted to investigate if the mRNA vaccine technology could be adapted for the ectothermic vertebrate Atlantic salmon (Salmo salar). The lipid nanoparticle (LNP) technology has been developed and optimized for mRNA vaccines in mammals, stabilizing mRNA and facilitating delivery into cells. However, its utility at the temperature and specific biological environment in ectotherms remains unclear. In addition, it is unknown if modified mRNA containing non-canonical nucleotides can correctly translate in salmonid cells. Methods: We used an mRNA transcript coding for enhanced green fluorescence protein, flanked by the untranslated regions of the hemagglutinin-esterase gene of infectious salmon anemia virus, and a 120-base-long poly(A) tail. The mRNA was generated by in vitro transcription where uridine residues were replaced with N1-methyl-pseudouridines, and then encapsulated in LNPs. Results: When transfected into the salmonid cell line CHH-1, the mRNA-LNP construct induced expression of EGFP. Furthermore, when mRNA-LNPs were injected intramuscularly into salmon, in vivo protein expression was demonstrated by immunohistochemistry. EGFP was observed in cells infiltrating the space between the muscle cells in a focal inflammatory response. Conclusion: The results indicate that the N1-methyl-pseudouridine modified mRNA encapsulated in LNPs can be used to express antigens of interest in salmonid fish.
Actin is a critical component of the eukaryotic cytoskeleton. In animals, actins undergo unique N-terminal processing by dedicated enzymes resulting in mature acidic and acetylated forms. The final step, N-terminal acetylation, is catalyzed by NAA80 in humans. N-terminal acetylation of actin is crucial for maintaining normal cytoskeletal dynamics and cell motility in human cell lines. However, the physiological impact of actin N-terminal acetylation remains to be fully understood. We developed a zebrafishnaa80knockout model and demonstrated that Naa80 acetylates both muscle and non-muscle actins in vivo. Assays with purified Naa80 revealed a preference for acetylating actin N-termini. Zebrafish lacking actin N-terminal acetylation exhibited normal development, morphology, and behavior. In contrast, humans with pathogenic actin variants can present with hypotonia and hearing impairment. Whereas zebrafish lackingnaa80showed no obvious muscle defects or abnormalities, we observed abnormal inner ear development, small otoliths, and impaired response to sound. In conclusion, we have established that zebrafish Naa80 N-terminally acetylates actins in vitro and in vivo, and that actin N-terminal acetylation is essential for normal hearing.
Infectious salmon anemia (ISA) is a disease affecting Atlantic salmon that historically has caused large economic losses in salmon aquaculture. The implementation of various biosecurity measures, including vaccination, has reduced the number of ISA outbreaks. mRNA vaccines have emerged as a potent prophylactic tool against various viral diseases in mammals, but their application in aquaculture is still in the early stages of development. In this study, N1-methyl-pseudoruridine-modified mRNAs encoding the ISAV hemagglutinin-esterase (HE) and fusion (F) surface glycoproteins were in vitro transcribed and encapsulated in lipid nanoparticles (LNPs). Atlantic salmon were intramuscularly injected with either 10 µg HE mRNA-LNPs, 10 µg F mRNA-LNPs, 10 µg HE and 10 µg F mRNA-LNPs, 10 µg mock mRNA-LNPs or Tris-HCl and then challenged with ISAV by a cohabitation model. In the challenge trial, none of the immunized fish groups demonstrated protection against ISA.
Infectious salmon anaemia (ISA) affects Atlantic salmon ( Salmo salar ) and is caused by the ISA virus (ISAV). The disease is associated with ISAV strains with deletions in the hemagglutinin‐esterase protein, named HPRΔ variants. The present study was initially designed as a vaccine efficacy study against ISA. Considerable variability in mortality in virus‐injected fish was observed in repeated experimental challenges using the NO/Finnmark/NVI‐70‐72/2020 isolate. Four independent experimental challenge trials were conducted. In two experiments, high cumulative mortality was seen in intraperitoneally (i.p.) injected fish. In contrast, considerably lower cumulative mortality was observed in i.p. injected fish in two other experiments. Mortality among cohabitant fish was moderate in one experiment and low or absent in two others. The observed inconsistency precluded reliable assessment of vaccine efficacy and implied investigation into factors underlying the outcome reproducibility between the experimental challenges. To investigate the observed variation in outcomes, fish, virus, and physical conditions were compared in detail. One notable difference among the challenge experiments was tank volume. Mortality was higher among fish injected with virus in smaller tanks than in larger ones. Further examination of the physical and biological variables failed to identify any other definitive determining factors. In addition, to investigate whether the comparatively delayed mortality induced by the injected NO/Finnmark/NVI‐70‐72/2020 isolate was associated with early virus–host interactions, a time‐course study was conducted to quantify relative viral RNA levels and innate immune responses in ASK‐II cells. A highly virulent isolate induced greater expression of innate immune response genes, which may be attributable to the higher amount of viral RNA present in the inoculum despite comparable levels of infectious virus. Collectively, these findings suggest that subtle differences in experimental conditions may contribute to variation in disease outcome and indicate that further research is required to improve understanding of fundamental ISAV biological characteristics.